Articles

September 2, 2019 ORION-11: A Landmark Event for RNAi Therapeutics The results from the ORION-11 Phase 3 study of inclisiran, presented earlier today at the European Society of Cardiology meeting represent a landmark event... Read More ›
August 8, 2019 Call for Entries: Deadline Extended - Submit Your Original Art Depicting Life with hATTR A ... “The Art of Living with hATTR Amyloidosis” is a new initiative inviting members of the hereditary ATTR (hATTR) amyloidosis community – including patients... Read More ›
June 24, 2019 Alnylam Honored by NORD with a Rare Impact Award Alnylam Honored by NORD with a Rare Impact Award for the development and approval of ONPATTRO (patisiran). Read More ›
June 21, 2019 Alnylam Launches PH1 of a Kind - An Animated Video Series for Kids with PH1 Yesterday, at the OHF International Hyperoxaluria Workshop in Boston, Alnylam previewed PH1 of a Kind, a new animated video series for children about living... Read More ›
June 11, 2019 Pride 2019 - Alnylam Celebrates Diversity at Boston Pride Parade This past Saturday, Alnylam joined approximately 750,000 people gathered in Boston for the 2019 Boston Pride Parade to honor the 50th anniversary of the... Read More ›
June 10, 2019 Alnylam Named a Best Workplace in Switzerland & UK Alnylam's offices in Maidenhead, UK and Zug, Switzerland were both recently named to Great Place to Work's Best Workplaces for 2019. Read More ›
April 11, 2019 Letter to the Editor: Federal Research is Important, but Companies Turn it Into Actual Tre ... John Maraganore wrote a Letter to the Editor in The Washington Post about the importance of federal research... Read More ›
March 29, 2019 Team Alnylam Hits the Court to Support Massachusetts Special Olympics Alnylam joined more than a dozen biotech companies in the annual Bioball Basketball Tournament to support the Massachusetts Special Olympics. Read More ›
February 28, 2019 Meet the 2018 Advocacy for Impact Grants Recipients We are very pleased to announce the 2018-19 Advocacy for Impact Grants recipients and share more information about their initiatives. Advocacy for Impact is... Read More ›
February 20, 2019 Alnylam Named a Fast Company World's Most Innovative Company for 2019 Alnylam has been named #3 in Biotech on Fast Company's World's 50 Most Innovative Company for 2019. Read More ›
Subscribe to Articles

FOLLOW US

Visit our social channels to learn more about the innovative work we are doing at Alnylam.

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site